English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

In this paper, we review certain aspects of the new guideline on the clinical development of medicinal products intended for the treatment of pain of the European Medicines Agency, which came into effect July 2017. The content the new guideline seems to be especially of value for the development of oral or parenteral analgesics, and is less relevant for topical formulations, which increasingly are recognized as important new therapeutic modalities for neuropathic pain. The guideline discusses the importance of targeting the population, and points out that new, innovative development designs are welcomed. We will present aspects of such designs. Cross-over studies, enrichment and withdrawal designs are discussed, and for the development of a topical analgesic, the latter study designs are better fit to capture clear efficacy versus placebo. For repurposing of old drugs in the field of pain, consultation with competent authorities (national or centrally via EMA) is advised, to discuss in depth what is required to obtain a marketing authorization for an old repositioned drug on a case-bycase basis.

Development issues related todesigns in neuropathic pain in light of the European MedicinesAgency’s (EMA) Guideline for the treatment of pain